i-SENS, Inc. (099190.KQ)
KRW 15190.0
(-0.72%)
KRW 15190.0
(-0.72%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 24.14 Billion KRW | -24.76% |
| 2022 | 31.86 Billion KRW | -30.23% |
| 2021 | 44.72 Billion KRW | 8.09% |
| 2020 | 41.37 Billion KRW | 5.57% |
| 2019 | 40.18 Billion KRW | 12.12% |
| 2018 | 35.23 Billion KRW | 16.58% |
| 2017 | 27.94 Billion KRW | -4.54% |
| 2016 | 31.41 Billion KRW | 16.35% |
| 2015 | 26.99 Billion KRW | 7.81% |
| 2014 | 25.04 Billion KRW | 0.79% |
| 2013 | 24.84 Billion KRW | 88.41% |
| 2012 | 15.92 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 3.82 Billion KRW | -36.81% |
| 2024 Q1 | 4.51 Billion KRW | 19.0% |
| 2024 Q2 | 1.97 Billion KRW | 24.22% |
| 2023 Q2 | 6.95 Billion KRW | -7.81% |
| 2023 FY | - KRW | -24.76% |
| 2023 Q1 | 7.54 Billion KRW | 289.56% |
| 2023 Q3 | 2.78 Billion KRW | -60.03% |
| 2023 Q4 | 7.16 Billion KRW | 157.82% |
| 2022 Q2 | 10.18 Billion KRW | -18.43% |
| 2022 Q1 | 12.48 Billion KRW | 53.94% |
| 2022 FY | - KRW | -30.23% |
| 2022 Q4 | 1.93 Billion KRW | -70.99% |
| 2022 Q3 | 6.67 Billion KRW | -34.4% |
| 2021 FY | - KRW | 8.09% |
| 2021 Q2 | 13.67 Billion KRW | 26.97% |
| 2021 Q3 | 12.06 Billion KRW | -11.83% |
| 2021 Q1 | 10.77 Billion KRW | 28.13% |
| 2021 Q4 | 8.1 Billion KRW | -32.78% |
| 2020 Q3 | 11.6 Billion KRW | 4.75% |
| 2020 FY | - KRW | 5.57% |
| 2020 Q4 | 8.4 Billion KRW | -27.52% |
| 2020 Q2 | 11.07 Billion KRW | 7.6% |
| 2020 Q1 | 10.29 Billion KRW | 2.7% |
| 2019 FY | - KRW | 12.12% |
| 2019 Q4 | 10.02 Billion KRW | 0.12% |
| 2019 Q3 | 10 Billion KRW | -12.57% |
| 2019 Q2 | 11.44 Billion KRW | 31.44% |
| 2019 Q1 | 8.71 Billion KRW | -24.1% |
| 2018 Q3 | 9.46 Billion KRW | 47.94% |
| 2018 FY | - KRW | 16.58% |
| 2018 Q2 | 6.39 Billion KRW | -16.02% |
| 2018 Q1 | 7.61 Billion KRW | 4.84% |
| 2018 Q4 | 11.47 Billion KRW | 21.27% |
| 2017 Q2 | 7.52 Billion KRW | 0.24% |
| 2017 FY | - KRW | -4.54% |
| 2017 Q1 | 7.5 Billion KRW | -7.4% |
| 2017 Q3 | 7.7 Billion KRW | 2.43% |
| 2017 Q4 | 7.26 Billion KRW | -5.77% |
| 2016 FY | - KRW | 16.35% |
| 2016 Q2 | 8.21 Billion KRW | 21.43% |
| 2016 Q1 | 6.76 Billion KRW | -2.49% |
| 2016 Q3 | 8.31 Billion KRW | 1.21% |
| 2016 Q4 | 8.1 Billion KRW | -2.52% |
| 2015 Q1 | 5.77 Billion KRW | -16.59% |
| 2015 Q4 | 6.94 Billion KRW | -0.15% |
| 2015 Q2 | 7.18 Billion KRW | 24.54% |
| 2015 Q3 | 6.95 Billion KRW | -3.3% |
| 2015 FY | - KRW | 7.81% |
| 2014 Q3 | 6.65 Billion KRW | 17.56% |
| 2014 FY | - KRW | 0.79% |
| 2014 Q1 | 5.71 Billion KRW | -16.35% |
| 2014 Q4 | 6.91 Billion KRW | 4.03% |
| 2014 Q2 | 5.65 Billion KRW | -1.07% |
| 2013 Q1 | 5.32 Billion KRW | 34.28% |
| 2013 Q2 | 6.21 Billion KRW | 16.6% |
| 2013 FY | - KRW | 88.41% |
| 2013 Q3 | 6.39 Billion KRW | 2.95% |
| 2013 Q4 | 6.83 Billion KRW | 6.88% |
| 2012 Q3 | 2.57 Billion KRW | 0.0% |
| 2012 Q4 | 3.96 Billion KRW | 53.92% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 157.89 Billion KRW | 84.708% |
| InBody Co.,Ltd | 44.25 Billion KRW | 45.446% |
| Curexo Inc. | -2.75 Billion KRW | 976.83% |
| Seegene, Inc. | 35.65 Billion KRW | 32.283% |
| Ray Co., Ltd. | 7.62 Billion KRW | -216.687% |
| Gencurix Inc. | -18.09 Billion KRW | 233.45% |
| Sugentech Inc. | -12.13 Billion KRW | 299.027% |
| L&C Bio Co., Ltd | 13.4 Billion KRW | -80.155% |